The short version
- The personalized vaccine, called Intismeran, extended recurrence-free survival in patients with high-risk melanoma when used with Keytruda.
- The trial involved over 1,000 patients and demonstrated statistically significant reductions in cancer spread and return.
- Experts caution that full peer-reviewed data is pending, and regulatory approval remains a necessary next step.
Pharmaceutical companies Moderna and Merck announced successful Phase 3 trial results for a personalized mRNA vaccine designed to treat melanoma, one of the deadliest forms of skin cancer. The vaccine, known as Intismeran (or mRNA-4157), was administered in combination with Keytruda, an existing immunotherapy drug. Early data indicates that the combination therapy significantly extended the time patients remained cancer-free and reduced the risk of the disease spreading to other organs compared to Keytruda alone.
The Phase 3 trial included 1,137 patients with high-risk stage IIB through IV melanoma who had undergone surgical removal of their tumors. Participants were randomized to receive either the combination treatment or Keytruda alone for approximately one year. The study was double-blind and placebo-controlled, ensuring that neither doctors nor patients knew which treatment group they belonged to. Based on a planned interim analysis, both recurrence-free survival and distant metastasis-free survival showed statistically significant improvements in the vaccine group.
Intismeran represents a novel approach to cancer treatment by targeting specific mutations within an individual patient's tumor cells. Using mRNA technology similar to that employed in COVID-19 vaccines, scientists sequence the DNA of a small sample of the patient's tumor to identify unique genetic alterations. The vaccine is then custom-made to instruct the immune system to recognize and attack these specific cancer cells. This personalized strategy aims to enhance the body's natural defenses against residual cancer cells after surgery.
Stephane Bancel, chief executive of Moderna, described the findings as a "pivotal moment" in cancer research. The announcement led to a surge in shares for both Moderna and Merck, reflecting investor optimism about the potential commercial impact of the therapy. Previous data from a five-year Phase 2 trial had shown a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant metastasis or death, further bolstering confidence in the treatment's efficacy.
Despite the positive results, cancer experts urge caution. Dr. Talisia Quallo, head of prevention and early detection at Cancer Research UK, noted that while the research "shows promise," the interim data still requires full review and peer validation. Independent experts must examine the trial findings to confirm their reliability before broader conclusions can be drawn. The full results have not yet been released or subjected to this rigorous scientific scrutiny.
Dr. Lennard Lee, a consultant medical oncologist at the University of Oxford, echoed these sentiments, highlighting that while the news is encouraging for melanoma patients, the study has limitations. The treatment would still need to undergo regulatory approval processes in various countries before it becomes available to the public. In the UK, for instance, it would require approval from health authorities and subsequent integration into NHS protocols.
Moderna and Merck are currently testing similar personalized vaccines for other types of cancer, including lung, bladder, and kidney cancers. The success in melanoma could pave the way for broader applications of mRNA-based neoantigen therapy across different oncological conditions. This approach avoids traditional chemotherapy side effects by focusing on precise immune responses tailored to individual patients.
The companies plan to present the detailed data at an upcoming international medical conference, providing researchers and clinicians with more comprehensive insights into the trial's outcomes. Until then, the medical community awaits further verification of these promising results. The potential for personalized cancer vaccines to revolutionize treatment options remains a significant area of interest and investment.
Patients and families affected by melanoma are watching these developments closely, hoping for new avenues of hope. The combination of surgery, immunotherapy, and personalized vaccination offers a multi-faceted strategy against aggressive skin cancers. However, the path from clinical trial success to widespread availability is long and complex, involving regulatory hurdles and manufacturing challenges.
As the scientific community digests these findings, the focus shifts to understanding the long-term durability of the treatment's effects. While early results are encouraging, determining how long patients remain cancer-free will be crucial for assessing the therapy's true value. The collaboration between Moderna and Merck exemplifies the power of combining innovative technology with established pharmaceutical expertise to tackle difficult medical challenges.
Sources behind this briefing
Go to the original reporting
- BBC News↗Vaccine breakthrough stops cancer returning in trial
- Ars Technica↗mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
- CNBC↗Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
- Reuters↗Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope
